Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme

To investigate the relationship between angina pectoris and fatal and non‐fatal clinical outcomes in heart failure with reduced and preserved ejection fraction (HF‐REF and HF‐PEF, respectively).

[1]  J. Fleg,et al.  Hospitalizations due to unstable angina pectoris in diastolic and systolic heart failure. , 2007, The American journal of cardiology.

[2]  Sanjiv J Shah,et al.  Spironolactone for heart failure with preserved ejection fraction. , 2014, The New England journal of medicine.

[3]  Goldberger Jj,et al.  Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. , 2014 .

[4]  P. Ponikowski,et al.  Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long‐Term Registry , 2013, European journal of heart failure.

[5]  L. Shaw,et al.  Heart failure with preserved ejection fraction: comparison of patients with and without angina pectoris (from the Duke Databank for Cardiovascular Disease). , 2014, Journal of the American College of Cardiology.

[6]  P. Poole‐Wilson,et al.  Symptoms in patients with heart failure are prognostic predictors: insights from COMET. , 2005, Journal of cardiac failure.

[7]  M. Pfeffer,et al.  Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators. , 1999, Journal of cardiac failure.

[8]  J. McMurray,et al.  Eplerenone in patients with systolic heart failure and mild symptoms. , 2011, The New England journal of medicine.

[9]  Salim Yusuf,et al.  Predictors of mortality and morbidity in patients with chronic heart failure. , 2006, European heart journal.

[10]  J. Rouleau,et al.  Navigating the Crossroads of Coronary Artery Disease and Heart Failure , 2006, Circulation.

[11]  C. O'connor,et al.  A standardized definition of ischemic cardiomyopathy for use in clinical research. , 2002, Journal of the American College of Cardiology.

[12]  Salim Yusuf,et al.  A multivariate model for predicting mortality in patients with heart failure and systolic dysfunction. , 2004, The American journal of medicine.

[13]  J. McMurray,et al.  Relationship between angina pectoris and outcomes in patients with heart failure and reduced ejection fraction: an analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). , 2014, European heart journal.

[14]  R. F. Kelly,et al.  Utility of history, physical examination, electrocardiogram, and chest radiograph for differentiating normal from decreased systolic function in patients with heart failure. , 2002, The American journal of medicine.

[15]  R. McKelvie,et al.  The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. , 2005, Journal of cardiac failure.

[16]  Akshay S. Desai,et al.  Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.

[17]  M. Pfeffer,et al.  Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme , 2003, The Lancet.

[18]  C. O'connor,et al.  Comparison of Clinical characteristics and long-term outcomes of patients with ischemic cardiomyopathy with versus without angina pectoris (from the Duke Databank for Cardiovascular Disease). , 2012, The American journal of cardiology.

[19]  K. Anstrom,et al.  Costs for heart failure with normal vs reduced ejection fraction. , 2006, Archives of internal medicine.

[20]  Susan Anderson,et al.  Irbesartan in patients with heart failure and preserved ejection fraction. , 2008, The New England journal of medicine.